Regenerative medicine company eQcell picks up C$1.1m in funding

The investor was Ag Capital Canada.

  • The funding will help eQcell advance its clinical stromal cell development programs and expand its therapeutic pipeline
  • eQcell is the first company in Canada to receive Health Canada authorization for the clinical testing of mesenchymal stromal cells for the treatment of equine and canine arthritis
  • Ag Capital Canada invests in agriculture and food technologies

Guelph, Ontario-based eQcell, a clinical-stage regenerative medicine company, has secured C$1.1 million in financing. The investor was Ag Capital Canada, a Canadian investor in agriculture and food technologies.

EQcell is the first company in Canada to receive Health Canada authorization for the clinical testing of mesenchymal stromal cells for the treatment of equine and canine arthritis.

The mesenchymal stromal cells (MSCs) produced by eQcell are the result of 15 years of research, development and treatment of horses and dogs at the University of Guelph’s Ontario Veterinary College.

Ag Capital Canada’s investment provides eQcell with additional funding to advance its clinical stromal cell development programs and expand its therapeutic pipeline. Horses and dogs with naturally occurring osteoarthritis tend to yield data that is more clinically relevant to human osteoarthritis than do traditional laboratory animal pre-clinical models.

John Lansink, a managing partner at Ag Capital Canada, said in a statement: “We at Ag Capital Canada have been following Dr. Koch and his research for several years now. The pioneering work he and his team are doing has the potential to change the availability and application of osteoarthritis treatments for the animal health industry.”